Pseudomonas aeruginosa Resistance – A Challenge in the Treatment of Healthcare-Associated Infections

Infections caused by Pseudomonas aeruginosa pose a significant threat to human health and are the main contributors to mortality in the United States, Japan, and Europe. These pathogens are the leading causes of nosocomial infections, particularly in immunosuppressed patients. P. aeruginosa develops re¬sistance to a wide range of antibiotics through various mechanisms, including efflux pumps, chromosomal mutations, and the production of beta-lactamases. The high heterogeneity among different strains and the ability to code for a diverse range of proteins make P. aeruginosa exceptionally difficult to treat. These characteristics complicate the development of effective therapeutic agents. New therapies are being ex¬plored to combat resistance, including antibiotic combinations and bacteriophages, which show promising results. Despite advances in research, infections caused by P. aeruginosa remain a significant social and health problem, requiring urgent measures to effectively manage antibiotic resistance effectively.